Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 staged study of Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines in Sierra Leone
PACTR201506001147964Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3 trial of zabdeno and Mvabea in Ebola virus disease (EVD) (5 arms), sponsored by Johnson & Johnson. Primary endpoints: Safety and Immunogenicity. Started Jun 2015; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR201506001147964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201506001147964.